Alpharma Generic Exclusivity Deals Will Face FTC Scrutiny Under Settlement
Alpharma has agreed to limits on future agreements with generic companies involving licensing of 180-day "first-to-file" exclusivity as part of a settlement with the Federal Trade Commission
You may also be interested in...
Purepac/Teva will not be able to market gabapentin capsules before December unless the companies reach an agreement with Apotex to settle a lawsuit challenging generic exclusivity rights to Pfizer's Neurontin. A federal appeals court granted Apotex' request to stay the ANDA approval of "first filer" Purepac pending resolution of Apotex' lawsuit against FDA. Purepac received approval in September 2003 but has not yet launched due to pending litigation; the company has selectively waived its 180-day exclusivity to Teva. The court's decision does not affect approvals Ivax has on tablet forms of gabapentin; Ivax says it is still considering when to launch...
Teva and Ivax are moving into position to consider "at risk" launches of generic gabapentin (Pfizer's Neurontin)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011